Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia.

Sylvain Audia, Maxime Samson, Matthieu Mahévas, Christophe Ferrand, Malika Trad, Marion Ciudad, Alexandrine Gautheron, Famky Seaphanh, Vanessa Leguy, Sabine Berthier, Bruno Salles, Laurent Martin, Bernard Lorcerie, Pablo Ortega-Deballon, Olivier Facy, Denis Caillot, Agnès Soudry-Faure, Marc Michel, Bertrand Godeau, Nicolas LarmonierPhilippe Saas, Nona Janikashvili, Bernard Bonnotte

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The pathogenic role of B cells in immune thrombocytopenia (ITP) has justified the therapeutic use of anti-CD20 antibodies such as rituximab (RTX). However, 60% of ITP patients do not respond to RTX. To decipher the mechanisms implicated in the failure of RTX, and because the spleen plays a well-recognized role in ITP pathogenesis, 12 spleens from ITP patients who had been nonresponders to RTX therapy were compared with 11 spleens from RTX-untreated ITP patients and 9 controls. We here demonstrate that in RTX-nonresponder ITP patients, preferential Th1 and Tc1 T lymphocyte polarizations occur, associated with an increase in splenic effector memory CD8(+) T-cell frequency. Moreover, in the RTX- nonresponder patient group, the CD8(+) T-cell repertoire displays a restricted pattern. In the blood, the phenotype of CD8(+) T cells before and after RTX treatment is not modified in responders or nonresponders. Altogether, these results demonstrate for the first time an activation of splenic CD8(+) T cells in ITP patients who did not respond to RTX and suggest their involvement in platelet destruction in these patients.

Original languageEnglish (US)
Pages (from-to)2477-2486
Number of pages10
JournalBlood
Volume122
Issue number14
DOIs
StatePublished - Oct 3 2013

Fingerprint

Idiopathic Thrombocytopenic Purpura
T-cells
Chemical activation
T-Lymphocytes
Spleen
Rituximab
Therapeutic Uses
Platelets
Anti-Idiotypic Antibodies
Blood
B-Lymphocytes
Blood Platelets
Cells
Polarization
Phenotype
Data storage equipment
Antibodies

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Audia, S., Samson, M., Mahévas, M., Ferrand, C., Trad, M., Ciudad, M., ... Bonnotte, B. (2013). Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood, 122(14), 2477-2486. https://doi.org/10.1182/blood-2013-03-491415

Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. / Audia, Sylvain; Samson, Maxime; Mahévas, Matthieu; Ferrand, Christophe; Trad, Malika; Ciudad, Marion; Gautheron, Alexandrine; Seaphanh, Famky; Leguy, Vanessa; Berthier, Sabine; Salles, Bruno; Martin, Laurent; Lorcerie, Bernard; Ortega-Deballon, Pablo; Facy, Olivier; Caillot, Denis; Soudry-Faure, Agnès; Michel, Marc; Godeau, Bertrand; Larmonier, Nicolas; Saas, Philippe; Janikashvili, Nona; Bonnotte, Bernard.

In: Blood, Vol. 122, No. 14, 03.10.2013, p. 2477-2486.

Research output: Contribution to journalArticle

Audia, S, Samson, M, Mahévas, M, Ferrand, C, Trad, M, Ciudad, M, Gautheron, A, Seaphanh, F, Leguy, V, Berthier, S, Salles, B, Martin, L, Lorcerie, B, Ortega-Deballon, P, Facy, O, Caillot, D, Soudry-Faure, A, Michel, M, Godeau, B, Larmonier, N, Saas, P, Janikashvili, N & Bonnotte, B 2013, 'Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia.', Blood, vol. 122, no. 14, pp. 2477-2486. https://doi.org/10.1182/blood-2013-03-491415
Audia, Sylvain ; Samson, Maxime ; Mahévas, Matthieu ; Ferrand, Christophe ; Trad, Malika ; Ciudad, Marion ; Gautheron, Alexandrine ; Seaphanh, Famky ; Leguy, Vanessa ; Berthier, Sabine ; Salles, Bruno ; Martin, Laurent ; Lorcerie, Bernard ; Ortega-Deballon, Pablo ; Facy, Olivier ; Caillot, Denis ; Soudry-Faure, Agnès ; Michel, Marc ; Godeau, Bertrand ; Larmonier, Nicolas ; Saas, Philippe ; Janikashvili, Nona ; Bonnotte, Bernard. / Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. In: Blood. 2013 ; Vol. 122, No. 14. pp. 2477-2486.
@article{09f79ccd238a4108887012bc2dc8e644,
title = "Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia.",
abstract = "The pathogenic role of B cells in immune thrombocytopenia (ITP) has justified the therapeutic use of anti-CD20 antibodies such as rituximab (RTX). However, 60{\%} of ITP patients do not respond to RTX. To decipher the mechanisms implicated in the failure of RTX, and because the spleen plays a well-recognized role in ITP pathogenesis, 12 spleens from ITP patients who had been nonresponders to RTX therapy were compared with 11 spleens from RTX-untreated ITP patients and 9 controls. We here demonstrate that in RTX-nonresponder ITP patients, preferential Th1 and Tc1 T lymphocyte polarizations occur, associated with an increase in splenic effector memory CD8(+) T-cell frequency. Moreover, in the RTX- nonresponder patient group, the CD8(+) T-cell repertoire displays a restricted pattern. In the blood, the phenotype of CD8(+) T cells before and after RTX treatment is not modified in responders or nonresponders. Altogether, these results demonstrate for the first time an activation of splenic CD8(+) T cells in ITP patients who did not respond to RTX and suggest their involvement in platelet destruction in these patients.",
author = "Sylvain Audia and Maxime Samson and Matthieu Mah{\'e}vas and Christophe Ferrand and Malika Trad and Marion Ciudad and Alexandrine Gautheron and Famky Seaphanh and Vanessa Leguy and Sabine Berthier and Bruno Salles and Laurent Martin and Bernard Lorcerie and Pablo Ortega-Deballon and Olivier Facy and Denis Caillot and Agn{\`e}s Soudry-Faure and Marc Michel and Bertrand Godeau and Nicolas Larmonier and Philippe Saas and Nona Janikashvili and Bernard Bonnotte",
year = "2013",
month = "10",
day = "3",
doi = "10.1182/blood-2013-03-491415",
language = "English (US)",
volume = "122",
pages = "2477--2486",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "14",

}

TY - JOUR

T1 - Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia.

AU - Audia, Sylvain

AU - Samson, Maxime

AU - Mahévas, Matthieu

AU - Ferrand, Christophe

AU - Trad, Malika

AU - Ciudad, Marion

AU - Gautheron, Alexandrine

AU - Seaphanh, Famky

AU - Leguy, Vanessa

AU - Berthier, Sabine

AU - Salles, Bruno

AU - Martin, Laurent

AU - Lorcerie, Bernard

AU - Ortega-Deballon, Pablo

AU - Facy, Olivier

AU - Caillot, Denis

AU - Soudry-Faure, Agnès

AU - Michel, Marc

AU - Godeau, Bertrand

AU - Larmonier, Nicolas

AU - Saas, Philippe

AU - Janikashvili, Nona

AU - Bonnotte, Bernard

PY - 2013/10/3

Y1 - 2013/10/3

N2 - The pathogenic role of B cells in immune thrombocytopenia (ITP) has justified the therapeutic use of anti-CD20 antibodies such as rituximab (RTX). However, 60% of ITP patients do not respond to RTX. To decipher the mechanisms implicated in the failure of RTX, and because the spleen plays a well-recognized role in ITP pathogenesis, 12 spleens from ITP patients who had been nonresponders to RTX therapy were compared with 11 spleens from RTX-untreated ITP patients and 9 controls. We here demonstrate that in RTX-nonresponder ITP patients, preferential Th1 and Tc1 T lymphocyte polarizations occur, associated with an increase in splenic effector memory CD8(+) T-cell frequency. Moreover, in the RTX- nonresponder patient group, the CD8(+) T-cell repertoire displays a restricted pattern. In the blood, the phenotype of CD8(+) T cells before and after RTX treatment is not modified in responders or nonresponders. Altogether, these results demonstrate for the first time an activation of splenic CD8(+) T cells in ITP patients who did not respond to RTX and suggest their involvement in platelet destruction in these patients.

AB - The pathogenic role of B cells in immune thrombocytopenia (ITP) has justified the therapeutic use of anti-CD20 antibodies such as rituximab (RTX). However, 60% of ITP patients do not respond to RTX. To decipher the mechanisms implicated in the failure of RTX, and because the spleen plays a well-recognized role in ITP pathogenesis, 12 spleens from ITP patients who had been nonresponders to RTX therapy were compared with 11 spleens from RTX-untreated ITP patients and 9 controls. We here demonstrate that in RTX-nonresponder ITP patients, preferential Th1 and Tc1 T lymphocyte polarizations occur, associated with an increase in splenic effector memory CD8(+) T-cell frequency. Moreover, in the RTX- nonresponder patient group, the CD8(+) T-cell repertoire displays a restricted pattern. In the blood, the phenotype of CD8(+) T cells before and after RTX treatment is not modified in responders or nonresponders. Altogether, these results demonstrate for the first time an activation of splenic CD8(+) T cells in ITP patients who did not respond to RTX and suggest their involvement in platelet destruction in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84887677172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887677172&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-03-491415

DO - 10.1182/blood-2013-03-491415

M3 - Article

C2 - 23963041

AN - SCOPUS:84887677172

VL - 122

SP - 2477

EP - 2486

JO - Blood

JF - Blood

SN - 0006-4971

IS - 14

ER -